Gelteq Ltd

Gelteq Limited is a biotechnology company that specializes in the formulation, development, and manufacturing of a proprietary, gel-based oral drug delivery system. Founded in 2017, the company utilizes a stable matrix that can integrate water-soluble components, lipids, and various compounds to address traditional limitations of oral delivery, such as swallowing difficulties (dysphagia), taste issues, and concerns regarding absorption and dosage effectiveness. By converting existing compounds into a gel format, Gelteq provides a platform intended to improve the accessibility and efficacy of treatments across pharmaceutical, nutraceutical, veterinary, and sports performance sectors. The company’s technology was developed in collaboration with Monash University’s Institute of Pharmaceutical Science.

This delivery system is designed to provide solutions for partners in commercial and academic industries, including end-to-end service for new product development, white-labeling of market-ready formulations, and management of clinical trial batches through to GMP-certified manufacturing. By offering an alternative to traditional oral delivery methods, Gelteq aims to improve patient adherence to treatment plans, thereby helping to mitigate the risk of long-term health complications associated with medication non-adherence. The company operates globally with headquarters in Australia and facilities supporting research, development, and scaling of its proprietary gel technology for international markets.